Legal & General Group Plc Buys New Shares in Palvella Therapeutics, Inc. $PVLA

Legal & General Group Plc purchased a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,994 shares of the company’s stock, valued at approximately $1,222,000.

A number of other hedge funds also recently made changes to their positions in the stock. Group One Trading LLC grew its stake in shares of Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares during the period. KBC Group NV acquired a new position in Palvella Therapeutics in the first quarter valued at $28,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Palvella Therapeutics during the second quarter valued at about $35,000. Price T Rowe Associates Inc. MD increased its stake in Palvella Therapeutics by 11.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,090 shares of the company’s stock worth $429,000 after acquiring an additional 433 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Palvella Therapeutics during the second quarter worth about $71,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Insiders Place Their Bets

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the sale, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at approximately $327,860.34. The trade was a 66.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher P. Kiritsy sold 313 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total value of $49,141.00. Following the completion of the transaction, the director owned 250 shares in the company, valued at approximately $39,250. This trade represents a 55.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 8,917 shares of company stock valued at $1,180,309. Company insiders own 17.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on PVLA shares. Chardan Capital upgraded Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Monday, June 29th. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Stephens reissued an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Finally, HC Wainwright restated a “buy” rating and set a $270.00 target price on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $209.14.

Palvella Therapeutics Stock Performance

Palvella Therapeutics stock opened at $157.24 on Monday. The stock’s 50 day moving average price is $148.35 and its 200 day moving average price is $129.80. The firm has a market capitalization of $2.27 billion, a PE ratio of -32.55 and a beta of -0.25. Palvella Therapeutics, Inc. has a one year low of $52.36 and a one year high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, analysts forecast that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.